What does this research mean for the field?

Obinutuzumab provides rapid and sustained clinical improvement in patients with severe, rituximab-refractory pemphigus vulgaris. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the clinical efficacy of obinutuzumab in a patient with severe pemphigus vulgaris refractory to standard therapies including rituximab.

August 30, 2026Anais Brasileiros de DermatologiaOpen Access

Successful treatment of rituximab-refractory pemphigus vulgaris with Obinutuzumab

View Full Paper

Ask AI

Bookmark

Authors

TSTalha SaraçAnkara University MAMerve Aygün AlızadaAnkara University HMHandan Merve Erol MartAnkara University

Discussion

Member takes

Implication

Case report demonstrates rapid clinical remission with obinutuzumab in rituximab-refractory pemphigus vulgaris, highlighting an effective alternative therapy.

Key Points

To evaluate the clinical efficacy of obinutuzumab in a patient with severe pemphigus vulgaris refractory to standard therapies including rituximab.
Administered obinutuzumab at a dose of 1000 mg on days 1, 8, and 15 with standard premedication in an individual with a 10-year history of treatment-resistant disease.
Assessed disease severity at baseline, one month, and six months using the Pemphigus Disease Area Index (PDAI) activity and damage subscores.
Total PDAI score decreased from 73 (activity: 60, damage: 13) at baseline to 21 (activity: 12, damage: 9) at one month post-treatment.
Disease activity achieved sustained suppression at six months, with total PDAI dropping to 7 (activity: 3, damage: 4).

Cite This Study

Saraç et al. (2026) studied this question.

synapsesocial.com/papers/6a93f0f56c1a8fb52e79d8a8 https://doi.org/10.1016/j.abd.2026.501457

View Full Paper

Ask AI

Bookmark

Implication

Case report demonstrates rapid clinical remission with obinutuzumab in rituximab-refractory pemphigus vulgaris, highlighting an effective alternative therapy.

Successful treatment of rituximab-refractory pemphigus vulgaris with Obinutuzumab

Discussion

Member takes

Implication

Key Points

Cite This Study

Successful treatment of rituximab-refractory pemphigus vulgaris with Obinutuzumab

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider